Lemercier Jean-Luc M's Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 10, 2022
- Accession no.
- 0001225208-22-006814
- Filed
- May 10, 2022
- Trade date
- May 7-9, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.14M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lemercier Jean-Luc MCIK 0001710625 | Officer (CVP, EMEA, Canada, Latin Amer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2022 | Common Stock | FTax withholdingDisposed | −51 | $100.52 | −$5,126.52 | 154,983.34 | Direct | |
| May 8, 2022 | Common Stock | MOption exerciseAcquired | +8,531 | $0.00F1 | $0 | 163,514.34 | Direct | |
| May 8, 2022 | Common Stock | FTax withholdingDisposed | −615 | $100.52 | −$61,819.8 | 162,899.34 | Direct | |
| May 9, 2022 | Common Stock | MOption exerciseAcquired | +11,560 | $21.76 | +$251,545.6 | 174,459.34 | Direct | |
| May 9, 2022 | Common Stock | SSaleDisposed | −11,560 | $98.24F3 | −$1,135,654.4 | 162,899.34 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 8, 2022 | Common Stock | MOption exerciseDisposed | −8,531 | $0.00 | $0 | 0 | Direct | |
| May 9, 2022 | Common Stock | MOption exerciseDisposed | −11,560 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $97.95 to $98.66. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.